Mucosal healing in Crohn's disease and ulcerative colitis: What does it tell us?

Current Opinion in Gastroenterology

Volumn 27, Issue 4, 2011, Pages 342-345

  Flynn, Ann ^a   Kane, Sunanda ^b  

^a INDIANA UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Crohn's disease; mucosal healing; ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; LACTOFERRIN;

COLON RESECTION; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; ENDOSCOPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; LONG TERM CARE; PATIENT CARE; PREDICTION; RECURRENT DISEASE; REVIEW; SIGMOIDOSCOPY; STEROID THERAPY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 85027937516     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283455c8f     Document Type: Review

References (17)

1. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963. (Pubitemid 20338451)
2. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25:665-672. (Pubitemid 14122134)
3. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33:331-335.
4. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468. This is a prospective follow-up study of a previously published cohort of patients with Crohn's disease. This study suggests that endoscopic remission at 2 years, assessed by SES-CD, predicts future steroid-free remission at years 3 and 4.
5. Bjorkesten CG, Nieminen U, Turunen U, et al. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis 2010 [Epub ahead of print]. A retrospective evaluation of 71 patients with active luminal Crohn's disease treated with infliximab from 1999 to 2007. Results suggest that mucosal healing at 3 months predicted mucosal healing at 12 months; however, 12-month endoscopic findings were only available for a subset of patients.
6. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442. (Pubitemid 43261469)
7. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667. (Pubitemid 351284485)
8. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6:1218-1224.
9. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102:1647-1653.
10. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease: evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98:811-818. (Pubitemid 20095830)
11. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395. A randomized, double-blind, placebo-controlled trial including 169 patients treated with infliximab and placebo, azathioprine and placebo, or combination therapy for 30 weeks plus a 20-week extension trial, with a primary endpoint of steroid-free remission at week 26 and secondary endpoint of mucosal healing at week 26. This landmark study demonstrated improved steroid-free remission and mucosal healing at week 26 in patients receiving combination therapy.
12. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15:1295-1301. This retrospective cohort study of 214 patients with Crohn's disease treated with infliximab from 1994 to 2008 demonstrated that patients with complete or partial mucosal healing had few surgeries, fewer hospitalizations.
13. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97:947-953. (Pubitemid 34408253)
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476. (Pubitemid 41770166)
15. Sandborn WJ, Rutgeerts P, Reinisch W, et al. Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of symptomatic remission, and corticosteroid-free state. In: American College of Gastroenterology Annual Scientific Meeting, Paper Presentation. San Antonio, TX; 2010. In this post hoc analysis of combined ACT I and ACT II data, mucosal healing was highly predictive of future clinical and endoscopic remission, as well as future colectomy-free probability.
16. Froslie KF, Jahnsen J, Mourn BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-422. (Pubitemid 47187355)
17. Parente F, Molteni M, Marino B, et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010; 105:1150-1157. This is a prospective study including 83 patients with their first diagnosis or flare of ulcerative colitis requiring high-dose systemic steroids for moderate to severe disease. Correlation was demonstrated between ultrasound and endoscopic score. Both scores predicted clinical activity at 15 months.